S100A1 and metastatic melanoma: In two distinct patient cohorts with metastatic urothelial cancer[25] receiving anti-PD-L1 (atezolizumab) treatment and metastatic melanoma receiving anti-PD-1 (pembrolizumab) treatment, we have substantiated the predictive capacity of the S100 score for checkpoint blockade.